Skip to search formSkip to main contentSkip to account menu

quinagolide

Known as: N,N-diethyl-N'-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propyl-3-benzo(g)quinolinyl)sulfamide, (3alpha,4aalpha,10abeta)-(+-)-isomer, quinagolide, (3alpha,4aalpha,10abeta)-(+-)-isomer 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

AminoquinolinesDopamine Agonists

Narrower (1)

quinagolide hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Prodopaminergic Drugs for Treating the Negative Symptoms of Schizophrenia: Systematic Review and Meta-analysis of Randomized Controlled Trials.
BACKGROUND The negative symptoms of schizophrenia pose a heavy burden on patients and relatives and represent an unmet… 
2008
2008
Comparison of the effects of cabergoline and bromocriptine in women with hyperprolactinemic amenorrhea
Objective: There are relatively few reports in the world comparing the beneficial and adverse effects of bromocriptine and… 
2007
2007
Expression of messenger RNA for transforming growth factor-beta1 and for transforming growth factor-beta receptors in peripheral blood of systemic lupus erythematosus patients treated with low doses…
The objective of this study was to determine the expression of transforming growth factor-beta1 messenger RNA (TGF-β1 mRNA) and… 
Review
2005
Review
2005
Treatment of pituitary tumors
The neurotransmitter/neuromodulator dopamine plays an important role in both the central nervous system and the periphery. In the… 
Review
2000
Review
2000
Quinagolide in the Management of Prolactinoma
Objective: This study reports a six year experience with quinagolide (CV205-502) in the treatment of 40 patients with… 
2000
2000
A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients
Quinagolide (QUI) and cabergoline (CAB) are dopamine agonists recently introduced for the treatment of hyperprolactinemia. In the… 
2000
2000
Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
OBJECTIVE A retrospective French multicenter analysis was carried out to assess changes in tumor volume and plasma prolactin… 
1996
1996
In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand
OBJECTIVE Knowledge of the dopamine D2 receptor status of pituitary tumours may play a predictive role in differential diagnosis… 
1994
1994
Inhibitory effects of the dopamine agonists quinagolide (CV 205-502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat.
The SMtTW tumor, a spontaneous PRL-secreting transplantable tumor, is the only available animal model sensitive to dopamine… 
1991
1991
Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.
Quinagolide (CV 205-502, Sandoz), an octahydrobenzo (g) quinoline, is a new non-ergot dopamine agonist which has specific D2… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)